Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Phase 2 Completed 15 enrolled National Cancer Institute (NCI)

NaSingle-groupOpen-labelTreatment

Summary

This phase II trial studies how well dasatinib works in treating patients with head and neck cancer that has come back or spread to other areas of the body. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start: 2007-07
Primary completion: 2010-02
Completion: 2010-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	dasatinib anhydrous	Small molecule	—	Oral

Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Summary

Timeline

Drugs

Indications